Foundayo
Tablet
- Supplements
- Multi-month
- Prescription
- Coaching support
- Clinical support
Newly authorised in the UK
Foundayo, also called orforglipron and sometimes described as the skinny pill, is a once-daily GLP-1 tablet authorised by the MHRA on 10 August 2026 for weight management and type 2 diabetes. Compare UK provider cards, listed prices and practical service details in one place.




One-off order: £119

One-off order: £139

One-off order: £139


One-off order: £179

One-off order: £199

One-off order: £199


What is it?
Orforglipron works on the GLP-1 pathway, the same broad appetite-signalling route associated with Wegovy and other modern weight-loss medicines. The difference people will notice first is practical: Foundayo is a daily weight-loss tablet rather than an injection.
It mimics GLP-1 activity, helping people feel fuller and reducing appetite when prescribed alongside diet and lifestyle support.
Foundayo is taken once daily as a tablet, and available medicine information says it can be taken with or without food.
Foundayo provider cards should be checked for listed price, dose, supply length, consultation route, delivery terms and provider details.
How it compares
These medicines are not interchangeable, and the right route depends on clinical suitability. This snapshot focuses on format, routine and how Foundayo compares with established weekly injection options.
| Medicine | Form | Routine | Published result | UK price |
|---|---|---|---|---|
| New tabletFoundayoOrforglipron | Daily tablet | No food or water restrictions | 11.2% in ATTAIN-1 | Compare live listings |
| InjectionMounjaroTirzepatide | Weekly injection | No meal timing rule | Higher trial averages | Compare live listings |
| InjectionWegovySemaglutide injection | Weekly injection | No meal timing rule | Around 15% in major trials | Compare live listings |
| TabletWegovy pillOral semaglutide | Daily tablet | Empty-stomach routine | 13.6% in trial data | Compare oral listings |
Available dose information lists 0.8mg as the starting dose, then step-ups through 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg where clinically suitable. A prescriber can adjust based on response and tolerability.
The most common side effects reported for GLP-1 medicines are usually nausea, constipation, diarrhoea and vomiting. Dose increases are one of the moments where people tend to notice them most.
Foundayo is not an over-the-counter slimming product. A registered prescriber should check eligibility, other medicines, health history and ongoing monitoring needs.
MHRA authorisation is an important regulatory step, but routine NHS weight-management access depends on separate NICE and NHS decisions.
Price alert
Get a short update when Foundayo prices, supply or provider listings change.
Questions
Not yet for routine weight-management access. MHRA authorisation covers safety, quality and efficacy, but NHS funding and rollout depend on separate NICE and NHS decisions.
The provider cards on this page show the Foundayo listings currently held in the Health Compare Hub weight-loss comparison data. Check each provider page before ordering because prices, stock and eligibility wording can change.
Use the provider cards on this page for the currently tracked listed prices. Always confirm the final checkout price, dose, supply length and consultation requirements with the provider.
Both are daily GLP-1 tablets, but Foundayo is designed to be taken with or without food and without water restrictions. Oral Wegovy has stricter timing rules around food, drink and other medicines.
Trial data and medicine information for GLP-1 treatments point mainly to digestive side effects such as nausea, constipation, diarrhoea and vomiting, especially around dose increases.
Foundayo is being searched for as the skinny pill because it is a weight-loss tablet rather than an injection. It is still a prescription-only medicine for people who meet clinical criteria, not an over-the-counter slimming aid.